Programmed death ligand-1 (PD-L1) expression is a key biomarker to screen patients for PD-1/PD-L1-targeted immunotherapy. However, a subjective assessment guide on PD-L1 expression of tumor-infiltrating immune cells (IC) scoring is currently adopted in clinical practice with low concordance. The...
tumors need to create new blood vessels to stay nourished. Some targeted therapies block the growth of these new blood vessels. Other targeted therapies pinpoint mutations common to NSCLC cancer cells. This can include changes in specific genes. ...
Taking a lead in tackling NSCLC Poseidon has used the modular platform to generate four assets, including a lead molecule (Fig. 1) that targets the checkpoint protein programmed death-ligand 1 (PD-L1) on cancer cells and CD3 on T cells to treat non-small-cell lung cancer (NSCLC). Other...
It may also be used alone foradvanced NSCLCif you have tried chemotherapy that contains platinum and it did not work or is no longer workingand, your tumor tests positive for “PD-L1”andif your tumor has an abnormal “EGFR” or “ALK” gene, you have also received an “EGFR” or “...
In addition, in EGFR/ALK-altered NSCLC, there was no difference in survival between patients with tumor PD-L1 < 1% vs. ≥ 1% [6]. Therefore, PD-L1 is not always reliable as a biomarker of immune efficacy in patients with advanced NSCLC. ICIs can also be used as adjuvant or ...
Abnormalities in the structure or function of mitochondria are very common in tumors, such as mitochondrial DNA (mtDNA) damage in tumor cells, which affects mitochondrial respiration and energy synthesis [46,47]. There is abundant evidence suggesting mitochondrial dysfunction is a potential trigger for...
However, it is only recently that the association of genetic profiles such as EGFR mutational status in NSCLC on clonogenic survival parameters has been described [32,33]. Similarly, cell lines have been used to investigate the role of p53 in sensitivity to radiation. It has been generally ...
A possible rationale for the NCCN and ACR guidelines is that HL relapse is most common in the first two years after first achieving CR, and functional cure of HL is defined as being in CR for 5 years. Earlier studies, such as the one by Zinzani et al., considered this notion outdated...
TECENTRIQ is a prescription medicine used to treat: Adults with a type of lung cancer called non-small cell lung cancer (NSCLC). TECENTRIQ may be used alone as your first treatment when your lung cancer: has spread or grown,and your cancer tests positive for “high PD-L1”,and ...
TA Phase 2 Study of Cemiplimab (ANTI-PD-1 ANTIBODY) in Combination with BNT116 (FIXVAC LUNG) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 ≥50% ...